Robust and protective immune responses induced by heterologous prime-boost vaccination with DNA-protein dimeric RBD vaccines for COVID-19
- PMID: 37436839
- DOI: 10.1002/jmv.28948
Robust and protective immune responses induced by heterologous prime-boost vaccination with DNA-protein dimeric RBD vaccines for COVID-19
Abstract
The coronavirus disease 2019 (COVID-19) pandemic posed great impacts on public health. To fight against the pandemic, robust immune responses induced by vaccination are indispensable. Previously, we developed a subunit vaccine adjuvanted by aluminum hydroxide, ZF2001, based on the dimeric tandem-repeat RBD immunogen, which has been approved for clinical use. This dimeric RBD design was also explored as an mRNA vaccine. Both showed potent immunogenicity. In this study, a DNA vaccine candidate encoding RBD-dimer was designed. The humoral and cellular immune responses induced by homologous and heterologous prime-boost approaches with DNA-RBD-dimer and ZF2001 were assessed in mice. Protection efficacy was studied by the SARS-CoV-2 challenge. We found that the DNA-RBD-dimer vaccine was robustly immunogenic. Priming with DNA-RBD-dimer followed by ZF2001 boosting induced higher levels of neutralizing antibodies than homologous vaccination with either DNA-RBD-dimer or ZF2001, elicited polyfunctional cellular immunity with a TH 1-biased polarization, and efficiently protected mice against SARS-CoV-2 infection in the lung. This study demonstrated the robust and protective immune responses induced by the DNA-RBD-dimer candidate and provided a heterologous prime-boost approach with DNA-RBD-dimer and ZF2001.
Keywords: COVID-19; DNA vaccine; SARS-CoV-2; ZF2001; heterologous prime-boost immunization; immune responses.
© 2023 Wiley Periodicals LLC.
Similar articles
-
Safety and immunogenicity of heterologous boost immunization with an adenovirus type-5-vectored and protein-subunit-based COVID-19 vaccine (Convidecia/ZF2001): A randomized, observer-blinded, placebo-controlled trial.PLoS Med. 2022 May 26;19(5):e1003953. doi: 10.1371/journal.pmed.1003953. eCollection 2022 May. PLoS Med. 2022. PMID: 35617368 Free PMC article. Clinical Trial.
-
Boosting with Multiple Doses of mRNA Vaccine after Priming with Two Doses of Protein Subunit Vaccine MVC-COV1901 Elicited Robust Humoral and Cellular Immune Responses against Emerging SARS-CoV-2 Variants.Microbiol Spectr. 2022 Oct 26;10(5):e0060922. doi: 10.1128/spectrum.00609-22. Epub 2022 Aug 25. Microbiol Spectr. 2022. PMID: 36005765 Free PMC article.
-
A tandem-repeat dimeric RBD protein-based covid-19 vaccine zf2001 protects mice and nonhuman primates.Emerg Microbes Infect. 2022 Dec;11(1):1058-1071. doi: 10.1080/22221751.2022.2056524. Emerg Microbes Infect. 2022. PMID: 35311493 Free PMC article.
-
Comparing the immune response and protective effect of COVID-19 vaccine under different vaccination strategies.Hum Vaccin Immunother. 2023 Dec 15;19(3):2273155. doi: 10.1080/21645515.2023.2273155. Epub 2023 Dec 19. Hum Vaccin Immunother. 2023. PMID: 38111370 Free PMC article. Review.
-
DNA vaccines for SARS-CoV-2: toward third-generation vaccination era.Expert Rev Vaccines. 2021 Dec;20(12):1549-1560. doi: 10.1080/14760584.2021.1987223. Epub 2021 Oct 28. Expert Rev Vaccines. 2021. PMID: 34582298 Free PMC article. Review.
Cited by
-
Vaccines based on the fusion protein consensus sequence protect Syrian hamsters from Nipah virus infection.JCI Insight. 2023 Dec 8;8(23):e175461. doi: 10.1172/jci.insight.175461. JCI Insight. 2023. PMID: 37917215 Free PMC article.
-
Both chimpanzee adenovirus-vectored and DNA vaccines induced long-term immunity against Nipah virus infection.NPJ Vaccines. 2023 Nov 4;8(1):170. doi: 10.1038/s41541-023-00762-3. NPJ Vaccines. 2023. PMID: 37925490 Free PMC article.
-
Protective RBD-dimer vaccines against SARS-CoV-2 and its variants produced in glycoengineered Pichia pastoris.PLoS Pathog. 2024 Aug 30;20(8):e1012487. doi: 10.1371/journal.ppat.1012487. eCollection 2024 Aug. PLoS Pathog. 2024. PMID: 39213280 Free PMC article.
References
REFERENCES
-
- Tan W, Zhao X, Ma X, et al. A novel coronavirus genome identified in a cluster of pneumonia cases-Wuhan, China 2019−2020. China CDC Wkly. 2020;2(4):61-62.
-
- Gao GF. Science-based COVID-19 vaccine development. Natl Sci Rev. 2021;8(10):nwab193.
-
- Dai L, Gao GF. Viral targets for vaccines against COVID-19. Nat Rev Immunol. 2021;21(2):73-82.
-
- Xu K, Dai L, Gao GF. Humoral and cellular immunity and the safety of COVID-19 vaccines: a summary of data published by 21 May 2021. Int Immunol. 2021;33(10):529-540.
-
- Xu K, Fan C, Han Y, Dai L, Gao GF. Immunogenicity, efficacy and safety of COVID-19 vaccines: an update of data published by 31 December 2021. Int Immunol. 2022;34(12):595-607.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous